Compare NTGR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTGR | FULC |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 696.7M | 687.4M |
| IPO Year | N/A | 2019 |
| Metric | NTGR | FULC |
|---|---|---|
| Price | $21.58 | $10.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $39.00 | $16.38 |
| AVG Volume (30 Days) | 403.6K | ★ 843.3K |
| Earning Date | 02-04-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $699,572,000.00 | N/A |
| Revenue This Year | $5.13 | N/A |
| Revenue Next Year | $2.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.88 | ★ 2752.05 |
| 52 Week Low | $18.75 | $2.32 |
| 52 Week High | $36.86 | $15.74 |
| Indicator | NTGR | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 32.35 | 49.32 |
| Support Level | $21.10 | $9.78 |
| Resistance Level | $22.33 | $11.28 |
| Average True Range (ATR) | 0.70 | 0.74 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 20.00 | 73.58 |
Netgear Inc provider of networking technologies for businesses, homes, and service providers. It delivers a wide range of intelligent solutions designed to unleash the full potential of connectivity. The group has two segments: NETGEAR for Business and Connected Home which offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of organizations of all sizes. The Connected Home segment offers connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, and Others. It conduct business across three geographic territories: Americas; Europe, Middle East and Africa; and Asia Pacific.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.